{"id":"cdd-plus-bortezomib","safety":{"commonSideEffects":[{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bortezomib inhibits the 26S proteasome, preventing degradation of pro-apoptotic proteins and leading to accumulation of cellular stress and apoptosis in cancer cells. The CDD component (likely a chemotherapy combination) provides additional cytotoxic activity. Together, this combination targets multiple pathways to enhance anti-tumor efficacy.","oneSentence":"CDD Plus Bortezomib combines a chemotherapy regimen (CDD) with bortezomib, a proteasome inhibitor that blocks protein degradation to trigger cancer cell death.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:05:11.072Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma (in combination with chemotherapy)"},{"name":"Lymphoma (investigational)"}]},"trialDetails":[{"nctId":"NCT02336386","phase":"PHASE3","title":"CDD Plus Bortezomib or CDDin Relapsed or Refractory Multiple Myeloma With Extramedullary Plasmacytoma","status":"UNKNOWN","sponsor":"Beijing Chao Yang Hospital","startDate":"2014-12","conditions":"Extramedullary Plasmacytoma","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Chemotherapy Plus Bortezomib"],"phase":"phase_3","status":"active","brandName":"CDD Plus Bortezomib","genericName":"CDD Plus Bortezomib","companyName":"Beijing Chao Yang Hospital","companyId":"beijing-chao-yang-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CDD Plus Bortezomib combines a chemotherapy regimen (CDD) with bortezomib, a proteasome inhibitor that blocks protein degradation to trigger cancer cell death. Used for Multiple myeloma (in combination with chemotherapy), Lymphoma (investigational).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}